Variables | n (%) | 5-year LRR (%) | p |
---|---|---|---|
Treatment era | |||
1999–2007 | 1915 (39.6) | 5.5 | < 0.001 |
2008–2014 | 2926 (60.4) | 2.8 | |
Age (years) | |||
Median | 51.1 ± 10.5 | ||
≤ 40 | 723 (14.9) | 7.5 | < 0.001 |
> 40 | 4118 (85.1) | 3.3 | |
Tumor quadrant | |||
Inner | 1255 (25.9) | 5.3 | < 0.001 |
Non-inner | 3486 (72.0) | 3.0 | |
Unknown | 100 (2.1) | 18.9 | |
pT stage | |||
T2 | 1954 (40.4) | 5.3 | 0.003 |
T1 | 2887 (59.6) | 3.0 | |
Molecular subtype | |||
Luminal | 3150 (65.0) | 2.8 | < 0.001 |
Her2 overexpression | 501 (10.3) | 5.0 | |
Triple-negative | 1076 (22.2) | 6.5 | |
Unknown | 114 (2.4) | 5.3 | |
LVI | |||
Yes | 184 (3.8) | 8.1 | 0.011 |
No | 4631 (95.7) | 4.0 | |
Unknown | 26 (0.5) | 11.6 | |
Tumor grade | |||
I and II | 2803 (57.9) | 3.3 | 0.012 |
III | 1137 (23.5) | 5.1 | |
Unknown | 901 (18.6) | 4.6 | |
Histology | |||
IDC | 4399 (90.9) | 4.0 | 0.356 |
ILC | 141 (2.9) | 1.9 | |
IMPC | 26 (0.5) | 0.0 | |
MBC | 4 (0.1) | 0.0 | |
Medullary carcinoma | 56 (1.2) | 6.0 | |
Other | 215 (4.4) | 2.4 | |
Adjuvant chemotherapy | |||
Yes | 3236 (66.8) | 2.1 | < 0.001 |
No | 1605 (33.2) | 4.8 | |
Endocrine therapy | |||
Yes | 3113 (64.3) | 2.8 | < 0.001 |
No | 1682 (34.7) | 6.1 | |
Unknown | 46 (1.0) | 0.0 | |
Median time (months) | 44.7 ± 21.6 | ||
Anti-Her2 target therapy | |||
Yes | 233 (4.8) | 3.4 | 0.372 |
No | 4580 (94.6) | 4.0 | |
Unknown | 28 (0.6) | 0.0 |